Your browser doesn't support javascript.
loading
Design of a mucin-selective protease for targeted degradation of cancer-associated mucins.
Pedram, Kayvon; Shon, D Judy; Tender, Gabrielle S; Mantuano, Natalia R; Northey, Jason J; Metcalf, Kevin J; Wisnovsky, Simon P; Riley, Nicholas M; Forcina, Giovanni C; Malaker, Stacy A; Kuo, Angel; George, Benson M; Miller, Caitlyn L; Casey, Kerriann M; Vilches-Moure, José G; Ferracane, Michael J; Weaver, Valerie M; Läubli, Heinz; Bertozzi, Carolyn R.
Afiliación
  • Pedram K; Department of Chemistry and Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Shon DJ; Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA.
  • Tender GS; Department of Chemistry and Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Mantuano NR; Department of Chemistry and Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Northey JJ; Cancer Immunotherapy Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Metcalf KJ; Division of Oncology, Department of Theragnostics, University Hospital, Basel, Switzerland.
  • Wisnovsky SP; Center for Bioengineering and Tissue Regeneration, Department of Surgery, University of California, San Francisco (UCSF), San Francisco, CA, USA.
  • Riley NM; Center for Bioengineering and Tissue Regeneration, Department of Surgery, University of California, San Francisco (UCSF), San Francisco, CA, USA.
  • Forcina GC; Department of Chemistry and Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Malaker SA; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Kuo A; Department of Chemistry and Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • George BM; Department of Chemistry and Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Miller CL; Department of Chemistry and Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Casey KM; Department of Chemistry, Yale University, New Haven, CT, USA.
  • Vilches-Moure JG; Department of Chemistry and Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Ferracane MJ; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Weaver VM; Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Läubli H; Brigham and Women's Hospital, Boston, MA, USA.
  • Bertozzi CR; Department of Chemistry and Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
Nat Biotechnol ; 42(4): 597-607, 2024 Apr.
Article en En | MEDLINE | ID: mdl-37537499
ABSTRACT
Targeted protein degradation is an emerging strategy for the elimination of classically undruggable proteins. Here, to expand the landscape of targetable substrates, we designed degraders that achieve substrate selectivity via recognition of a discrete peptide and glycan motif and achieve cell-type selectivity via antigen-driven cell-surface binding. We applied this approach to mucins, O-glycosylated proteins that drive cancer progression through biophysical and immunological mechanisms. Engineering of a bacterial mucin-selective protease yielded a variant for fusion to a cancer antigen-binding nanobody. The resulting conjugate selectively degraded mucins on cancer cells, promoted cell death in culture models of mucin-driven growth and survival, and reduced tumor growth in mouse models of breast cancer progression. This work establishes a blueprint for the development of biologics that degrade specific protein glycoforms on target cells.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Mucinas / Neoplasias Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Mucinas / Neoplasias Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Año: 2024 Tipo del documento: Article